ClinicalTrials.gg
RecruitingNCT07454980Updated Aug 28, 2026

Pivotal Trial to Evaluate TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (The TRINITY Pivotal Trial)

An interventional study of TTVI with LuX-Valve Plus System and TTVI with EVOQUE in Tricuspid Regurgitation (TR), sponsored by Jenscare Innovation Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Jenscare Innovation Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Tricuspid Valve Insufficiency with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Canada.

Planned enrollment
2nd of 10
680 · median 139
Started
2026
the only one that year
No phase
10 of 12
5 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Jenscare Innovation Inc.

Among the 12 studies in Tricuspid Valve Insufficiency with a site in Canada, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 12th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

7 of the 12 studies in Tricuspid Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Tricuspid Valve Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if LuX-Valve Plus system works to treat symptomatic subjects with at least severe tricuspid regurgitation (TR). It will also learn about the safety of LuX-Valve Plus system.

Researchers will compare LuX-Valve Plus system to a conventional device called EVOQUE to see if LuX-Valve Plus system works to treat subjects with at least severe tricuspid regurgitation.

Participants will:

Undergo one procedure using the LuX-Valve Plus system or EVOQUE after passing screening and enrolling in the trial; Complete follow-up visits and examinations as required by the trial protocol; Report any adverse events

03

Conditions studied

  • Tricuspid Regurgitation (TR)

Keywords

  • Tricuspid Regurgitation
  • Transvenous Tricuspid Replacement
  • LuX-Valve Plus System
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the randomized study:

  1. Subject is at least 21 years of age at time of consent.
  2. Subject (or legal guardian) understands trial requirements and treatment procedures and is able to provide written .
  3. Severe or greater TR as assessed on transthoracic echocardiography by core lab.
  4. (NYHA) Class II-IV.
  5. On optimal medical therapy (OMT) for TR at the time of baseline assessment per site Heart Team. OMT includes stable oral diuretic medications unless patient has a documented history of intolerance.
  6. The site Heart Team concurs that the patient is a good candidate for transcatheter tricuspid valve replacement and suitable for LuX-Valve Plus system by core lab.
  7. The commercial sponsor for EVOQUE deems that the patient is a good candidate for EVOQUE valve (control arm).

For single arm cohort ("Not Suitable for Conventional TTVI")

  1. Meets all criteria 1-6 above
  2. The EVOQUE commercial sponsor deems the anatomy unsuitable for EVOQUE tricuspid valve replacement, or the annular perimeter is smaller or greaterthan EVOQUE commercial Instructions for Use (IFU), as determined by the clinical site
  3. Two independent Structural Cardiologists determine the patient "Not Suitable" for Transcatheter edge to edge repair

Exclusion criteria

Exclusion Criteria:

  1. (LVEF) \<35%.
  2. Pulmonary arterial systolic pressure (PASP) >60 mmHg by echo Doppler (unless right heart catheterization [RHC] demonstrates PASP ≤60mmHg); in case RHC is performed, PASP >2/3 systemic BP with PVR >5 Wood units after vasodilator challenge, in the absence of symptomatic hypotension or systolic BP \<90 mmHg.
  3. Evidence of intracardiac mass, thrombus, or vegetation.
  4. Ebstein Anomaly or congenital right ventricular dysplasia.
  5. Surgical or interventional correction is indicated for other concomitant valvular diseases (subjects with concomitant valvular disease may treat their respective valve first and wait 30 days before being reassessed for the trial).
  6. Subjects with valve prostheses implanted in the tricuspid valve.
  7. Pre-existing prosthetic valve(s) (other than tricuspid ones) with prosthetic dysfunction.
  8. Active infection, infective endocarditis or sepsis within 3 months, or infections requiring antibiotics treatment within two weeks prior to planned procedure.
  9. Untreated clinically significant coronary artery disease requiring revascularization.
  10. Acute myocardial infarction or unstable ischemia-related angina within 30 days prior to the planned procedure.
  11. Any percutaneous coronary, intracardiac or carotid intervention within 30 days prior to the planned procedure.
  12. Cerebrovascular stroke (ischemic or bleeding) within 3 months prior to enrollment.
  13. Active peptic ulcer or active gastrointestinal bleeding within 3 months prior to enrollment.
  14. Blood dyscrasias as defined: leukopenia (WBC \<1000 mm3), thrombocytopenia ( count \<50,000 cells/mm3), history of bleeding diathesis, or coagulopathy.
  15. Inability to tolerate anticoagulation or antiplatelet therapy.
  16. Renal insufficiency (\< 30ml/min [per the CKD-EPI formula] and/or renal replacement therapy).
  17. Patients with hepatic insufficiency or cirrhosis with score class C
  18. Pregnancy or intent to become pregnant.
  19. Severe requiring or requiring continuous home oxygen.
  20. Untreatable or to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, or contrast media.
  21. Estimated \<12 months.
  22. Subjects currently participating in another clinical trial of an drug or device that has not yet completed its primary endpoint.
  23. Subjects with current history of illicit drug use.
  24. Any other condition making it unlikely the patient will be able to complete all protocol procedure and follow-ups determined by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
680 participants (estimated)

Study arms

  • Experimental
    Randomized cohort (EVOQUE Eligible Cohort): LuX-Valve

    Device: TTVI with LuX-Valve Plus System

  • Active comparator
    Randomized cohort (EVOQUE Eligible Cohort): EVOQUE

    Device: TTVI with EVOQUE

  • Experimental
    Single-arm cohort ("Not Suitable for Conventional TTVI"cohort): LuX-Valve

    Device: TTVI with LuX-Valve Plus System

Interventions

  • DeviceTTVI with LuX-Valve Plus System

    Transvenous tricuspid valve replacement with Lux-Valve Plus System in patients with severe or greater Tricuspid Regurgitation despite optimal medical therapy (OMT)

  • DeviceTTVI with EVOQUE

    Transvenous tricuspid valve replacement with EVOQUE in patients with severe or greater Tricuspid Regurgitation despite optimal medical therapy (OMT)

06

What researchers measure

Primary outcomes

  1. Rate of Major Adverse Events (MAE)

    Rate of Major Adverse Events (MAE) at 30 days consisting of the following components: * Cardiovascular Mortality * Myocardial Infarction (MI), periprocedural and spontaneous * All Stroke, disabling and non-disabling * New need for renal replacement therapy * Severe bleeding (includes type 3b or higher as defined by Tricuspid Valve Academic Research Consortium \[TVARC\] * Non-elective tricuspid valve re-intervention, surgery or transcatheter * Major access site and vascular complications * Major cardiac structural complications * Device-related pulmonary embolism * Arrhythmia and conduction disorders requiring permanent pacing

    Time frame: 30 Day Post-Procedure

  2. Rate of Composite Clinical Success

    Percentage (%) of participants achieving composite clinical success at 12 months. Composite clinical success is defined as meeting all of the following criteria: Patient survival, Free from heart failure hospitalization, No tricuspid valve surgery or percutaneous intervention

    Time frame: 12 Months Post-Procedure

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2029, 41 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 41 months is close to that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 6, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2038
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07454980
Lead sponsor
Jenscare Innovation Inc.
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Jul 15, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2038 (estimated)
Last update
Aug 28, 2026

Study contacts

Chen Jiao, MD
Contact
jiaochen@jenscare.com
+86 13816576611

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion